Moderate-dose dopamine (3-10 mcg/kg/min) activation involves which receptors and effects?

Moderate-dose dopamine (3-10 mcg/kg/min) activation involves which receptors and effects?

• A. Alpha1 only
• B. Beta1 & Beta2 (plus DA1); increases HR, CO, contractility
• C. DA1 only
• D. Beta2 only

Answer: (B)

The main concept is that dopamine’s effects depend on the dose, with moderate-dose mainly boosting cardiac performance and modestly dilating certain renal/mesenteric vessels. At 3–10 mcg/kg/min, dopamine stimulates beta-1 receptors in the heart, which increases heart rate and myocardial contractility. That rise in inotropy and chronotropy drives a higher cardiac output. Dopamine also activates D1 receptors in renal and mesenteric vessels, causing vasodilation in those beds and helping preserve or improve renal perfusion. Some peripheral beta-2 activity can occur, contributing minor vasodilation, but the dominant actions at this dose are beta-1–mediated cardiac enhancement and DA1–mediated vasodilation in certain vascular beds. That combination explains the observed increase in heart rate, contractility, and cardiac output. Higher doses shift toward alpha-1–mediated vasoconstriction, which is not the scenario described here, and a pure DA1 effect would miss the cardiac stimulation.

The main concept is that dopamine’s effects depend on the dose, with moderate-dose mainly boosting cardiac performance and modestly dilating certain renal/mesenteric vessels. At 3–10 mcg/kg/min, dopamine stimulates beta-1 receptors in the heart, which increases heart rate and myocardial contractility. That rise in inotropy and chronotropy drives a higher cardiac output. Dopamine also activates D1 receptors in renal and mesenteric vessels, causing vasodilation in those beds and helping preserve or improve renal perfusion. Some peripheral beta-2 activity can occur, contributing minor vasodilation, but the dominant actions at this dose are beta-1–mediated cardiac enhancement and DA1–mediated vasodilation in certain vascular beds. That combination explains the observed increase in heart rate, contractility, and cardiac output. Higher doses shift toward alpha-1–mediated vasoconstriction, which is not the scenario described here, and a pure DA1 effect would miss the cardiac stimulation.